





## Lung CD4+ T-cells in patients with lung fibrosis produce pro-fibrotic interleukin-13 together with interferon- $\gamma$

Liv I.B. Sikkeland<sup>1,2</sup>, Shuo-Wang Qiao <sup>©3,4</sup>, Thor Ueland <sup>©1,5,6</sup>, Ole Myrdal<sup>2</sup>, Łukasz Wyrożemski<sup>4</sup>, Pål Aukrust<sup>1,5,6,7</sup>, Frode L. Jahnsen<sup>1,8</sup>, Tone Sjåheim<sup>2</sup>, Johny Kongerud<sup>1,2</sup>, Øyvind Molberg<sup>1,9</sup>, May Brit Lund<sup>1,2</sup> and Espen S. Bækkevold<sup>8,10</sup>

Affiliations: <sup>1</sup>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. <sup>2</sup>Dept of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. <sup>3</sup>Dept of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet, Oslo, Norway. <sup>4</sup>K.G. Jebsen, Coeliac Disease Research Centre, University of Oslo, Oslo, Norway. <sup>5</sup>Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. <sup>6</sup>K.G. Jebsen, TREC, University of Tromsø, Tromsø, Norway. <sup>7</sup>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. <sup>8</sup>Dept of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway. <sup>9</sup>Dept of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway. <sup>10</sup>Institute of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.

Correspondence: Liv I.B. Sikkeland, Dept of Respiratory Medicine, Institute of Clinical Medicine, University of Oslo, N-0027 Oslo, Norway. E-mail: l.i.b.sikkeland@medisin.uio.no

## @ERSpublications

This study identified an unusual phenotype of clonally expanded CD4 T-cells in BAL in lung fibrosis characterised by co-production of pro-fibrotic cytokine IL-13 and pro-inflammatory cytokine IFN-γ. These cells may be a promising target for therapy. https://bit.ly/2TgzWCX

**Cite this article as:** Sikkeland LIB, Qiao S-W, Ueland T, *et al.* Lung CD4+ T-cells in patients with lung fibrosis produce pro-fibrotic interleukin-13 together with interferon-γ. *Eur Respir J* 2021; 57: 2000983 [https://doi.org/10.1183/13993003.00983-2020].

This single-page version can be shared freely online.

## To the Editor:

Progressive fibrosing interstitial lung diseases (PF-ILD) have poor prognosis and survival, and their pathogenesis is not well understood [1]. Mechanistically, lung fibrosis is thought to result from distorted wound-healing following tissue insults and inflammation, leading to scar formation by excess deposition of extracellular matrix proteins and destruction of lung architecture [2]. The fibrotic process is complex, and CD4+ T-cells are probably involved through their production of a wide range of cytokines and growth factors that promote fibroblast proliferation and differentiation, collagen production, and stimulate production of pro-fibrotic mediators by tissue macrophages [3]. However, CD4+ T-cells in PF-ILD are poorly characterised. To this end, we performed a detailed analysis of phenotype, cytokine production and clonality of T-cells from the lungs (bronchoalveolar lavage (BAL)) of PF-ILD patients. We found that BAL from PF-ILD lungs contained high numbers of clonally expanded CD4+ T-cells that produced an unusual combination of interferon (IFN)-γ and pro-fibrotic interleukin (IL)-13. Such cells were not found in patient blood or in control BAL samples.

Copyright ©ERS 2021